Cystatin C vs Creatinine eGFR in Advanced CKD: an analysis of the STOP-ACEi Trial
- Published on 09/04/2024
- Reading time: 4 min.
Sebastian Spencer, 1,2,3, Robert Desborough, 2,3, Samir Mehta, 4, Natalie Ives, 4, Sunil Bhandari 2,3
1 University of Hull
2 Hull York Medical School
3 Hull University Teaching Hospitals NHS Trust
4 Birmingham Clinical Trials Unit, University of Birmingham
Correspondence to: Sebastian Spencer; E-mail: sebastian.spencer2@nhs.net
Abstract
Background and hypothesis In this secondary analysis of the STOP-ACEi trial, we explored the impact of discontinuing or continuing renin angiotensin system inhibitor therapy in people with advanced chronic kidney disease on cystatin C estimated glomerular filtration rate.
Methods Cystatin C eGFR were calculated at baseline, 12-, 24- and 36-months using CKD-EPI Cystatin 2012, EKFC and CKD-EPI Combined 2021 equations. We excluded samples obtained after the...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Nephrology
Receive our newsletter to stay up to date with the latest news in Nephrology